Astrazeneca (AZN) Gains from Sales and Divestitures (2015 - 2026)

Astrazeneca (AZN) has reported Gains from Sales and Divestitures for 12 consecutive years, with -$34.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gains from Sales and Divestitures rose 48.48% year-over-year to -$34.0 million; the TTM figure through Mar 2026 stood at -$34.0 million (up 48.48% YoY), while the FY2025 annual figure was -$168.0 million, down 162.5% from the prior year.
• Gains from Sales and Divestitures came in at -$34.0 million for Q1 2026 at Astrazeneca, up from -$168.0 million in the prior quarter.
• The five-year high for Gains from Sales and Divestitures was -$10.0 million in Q1 2022, with the low at -$251.0 million in Q4 2023.
• Average Gains from Sales and Divestitures over 5 years is -$109.7 million, with a median of -$84.0 million recorded in 2022.
• Across the five-year window, Gains from Sales and Divestitures jumped 95.92% in 2022 and sank 2390.0% in 2023, its largest moves.
• Year by year, Gains from Sales and Divestitures stood at -$104.0 million in 2022, then tumbled by 141.35% to -$251.0 million in 2023, then surged by 74.5% to -$64.0 million in 2024, then plunged by 162.5% to -$168.0 million in 2025, then jumped by 79.76% to -$34.0 million in 2026.
• According to Business Quant data, Gains from Sales and Divestitures over the past three periods registered -$34.0 million, -$168.0 million, and -$118.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.